Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.
Moreau C, Odou P, Labreuche J, Demailly A, Touzet G, Reyns N, Gouges B, Duhamel A, Barthelemy C, Lannoy D, Carta N, Palas B, Vasseur M, Marchand F, Ollivier T, Leclercq C, Potey C, Ouk T, Baigne S, Dujardin K, Carton L, Rolland AS, Devedjian JC, Foutel V, Deplanque D, Fisichella M, Devos D
- DOI
- 10.1038/s41591-024-03428-2
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/00492f4a-f253-4538-b1d2-15ebcfbd5e23 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×3−1.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingStudy design partially met−0.25★
- ReportingStatistical analysis partially met−0.25★
- ReportingData & code availability partially met−0.25★
- Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy endpoint is the percentage over total target (time with dyskinesia or bradykinesia) recorded by actimetry, which is a surrogate/behavioral proxy for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor does it cite validated evidence linking this actimetry-based surrogate to a hard clinical outcome. The claim of efficacy rests on this surrogate without such validation.
“The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone ( P =…”
- 02Treatment effect not shown to be clinically meaningful
The primary effect size is a median within-patient difference of -10.4 percentage points (Hedge's g = -0.62), which is presented without an anchor to a minimal clinically important difference or to clinical meaningfulness. The paper acknowledges that the clinical interpretation of the primary endpoint is not obvious, and the effect is not explicitly anchored as clinically material.
“with a median within-patient difference of −10.4 (Hedge g = −0.62 (95% confidence interval: −1.43, −0.08))”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper is a well-conducted phase 1/2 crossover trial with a clear scientific premise, strong ethical approvals, and transparent reporting. The main weaknesses are the revised sample size without formal recalculation, partial blinding, vague data/code availability, and minor statistical reporting issues.
Both reviewers classified the study as interventional and agreed on all dimension statuses; no divergence to reconcile. The statistics component could not verify any tests due to lack of test statistics/df, and the GRIM/GRIMMER checks were not applicable to continuous data.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
- lowinternal contradictionTable 4 reports LEDD reduction percentages for 11 patients (patient 8 has no data), but the mean and median appear inconsistent with the individual values.
“LEDD reduction (%) | 36 | 63 | 51 | 58 | 38 | 53 | 41 | 15 | 42 | 53 | 31 | 44 | 42 (15, 63)”
Table 4Find in source - lowinternal contradictionThe mean LEDD reduction in Table 4 appears inconsistent with the individual values.
“LEDD reduction (%) | 36 | 63 | 51 | 58 | 38 | 53 | 41 | 15 | 42 | 53 | 31 | 44 | 42 (15, 63)”
Table 4Find in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
9 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewers 1, 2A-dopamine does not induce dyskinesia.The paper reports no dyskinesia induction in the acute challenge and chronic administration, but this is based on a small sample and short-term follow-up.Evidence: Acute challenge and phase 1/2 observations report no dyskinesia induction.
“The most surprising result was the absence of induction of dyskinesia as observed with acute and high-dose A-dopamine challenge and chronic administration.”
Discussion ¶2Find in source - partialReviewer 2The benefit of A-dopamine is maintained long-term (up to 3.5 years).Long-term follow-up data are presented, but the number of patients with long follow-up is small and the assessment is open-label.Evidence: Table 4 shows follow-up durations up to 42 months; no serious adverse reactions reported.
“With the first patient implanted in October 2020, there is now a maximum follow-up duration of over 3.5 years and a median follow-up period of 18 months”
ResultsFind in source - supportedReviewer 1Intracerebroventricular administration of anaerobic dopamine is safe in patients with Parkinson's disease.The paper reports no serious adverse reactions related to A-dopamine in phase 1 and long-term follow-up, supporting the safety claim.Evidence: Phase 1 safety data in Table 2 and long-term safety data in Table 4 show no severe adverse reactions related to A-dopamine.
“A phase 1/2 clinical trial of a new device-assisted therapy in Parkinson’s disease revealed that intracerebroventricular administration of anaerobic dopamine was safe and significantly reduced l -dopa-related complications.”
AbstractFind in source - supportedReviewer 1A-dopamine significantly reduces l-dopa-related complications compared to optimized oral therapy.The primary endpoint (percentage over total target) was significantly reduced (P=0.027) in the per-protocol analysis, supporting the claim.Evidence: Primary efficacy analysis showed a significant reduction in the primary outcome (P=0.027) with a medium effect size.
“The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone ( P = 0.027)”
AbstractFind in source - supportedReviewer 1A-dopamine improves home diary outcomes.Secondary outcomes from home diaries showed significant improvements, supporting the claim.Evidence: Table 3 shows improvements in various diary outcomes with effect sizes and CIs.
“Home diaries were also significantly improved.”
AbstractFind in source - supportedReviewer 1A-dopamine reduces the need for oral levodopa.The paper reports a substantial reduction in LEDD during phase 1 and long-term, supporting the claim.Evidence: Table 2 shows LEDD reduction of about 60% at end of phase 1; long-term data show 42% reduction.
“A dose of about 150 mg during the daytime allowed a levodopa equivalent daily dose (LEDD) reduction of about 60%.”
ResultsFind in source - supportedReviewer 2Intracerebroventricular anaerobic dopamine is safe and significantly reduces l-dopa-related complications in Parkinson's disease.The paper provides safety data from phase 1 and a significant primary endpoint result from the phase 2 crossover, supporting the claim.Evidence: Primary endpoint P=0.027, safety tables showing no serious adverse reactions.
A phase 1/2 clinical trial of a new device-assisted therapy in Parkinson’s disease revealed that intracerebroventricular administration of anaerobic dopamine was safe and significantly reduced l-dopa-related complications.
Abstractreviewer’s wording - supportedReviewer 2A-dopamine improves motor fluctuations and dyskinesia compared to optimized oral therapy.Secondary outcomes on actimetry and home diaries show significant improvements with medium to large effect sizes.Evidence: Table 3 shows improvements in time 'on' without dyskinesia, time in good autonomy, and reductions in dyskinesia scores.
“all secondary outcomes on home actimetry, home diaries and motor scale assessments were significantly improved (with medium to large effect sizes for A-dopamine)”
ResultsFind in source - supportedReviewer 2A-dopamine allows a significant reduction in oral l-dopa dose.LEDD reductions are reported in phase 1 and long-term phase, with a median reduction of about 60%.Evidence: Table 2 shows LEDD reduction percentages; long-term data show 42% median reduction.
“A dose of about 150 mg during the daytime allowed a levodopa equivalent daily dose (LEDD) reduction of about 60%.”
ResultsFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy endpoint is the percentage over total target (time with dyskinesia or bradykinesia) recorded by actimetry, which is a surrogate/behavioral proxy for clinical benefit. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor does it cite validated evidence linking this actimetry-based surrogate to a hard clinical outcome. The claim of efficacy rests on this surrogate without such validation.
“The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone ( P = 0.027)”
- INADEQUATEEffect sizeThe primary effect size is a median within-patient difference of -10.4 percentage points (Hedge's g = -0.62), which is presented without an anchor to a minimal clinically important difference or to clinical meaningfulness. The paper acknowledges that the clinical interpretation of the primary endpoint is not obvious, and the effect is not explicitly anchored as clinically material.
“with a median within-patient difference of −10.4 (Hedge g = −0.62 (95% confidence interval: −1.43, −0.08))”
Data authenticity concerns
1 finding · worst lowAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
- Methods and results do not matchAssessed
3 integrity concerns flagged (0 high).
- lowmethod result mismatchThe primary analysis excluded ~30% of evaluation weeks, which may introduce bias; the paper acknowledges this but the primary result is sensitive to this exclusion.
“around 30% of the evaluation weeks were not taken into account for noncompliance with oral treatment instructions.”
ResultsFind in source
Reporting gaps
3 findings · worst highRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
- Data/code availability incompleteAssessed
- Study-design details incomplete (controls, blinding, power)Assessed
The introduction cites prior studies on dopamine deficiency in PD, limitations of current treatments, and previous attempts at i.c.v. dopamine administration. It acknowledges the strengths and weaknesses of prior work, including the historical failure due to dopamine oxidation. The rationale for A-dopamine is logically derived from these limitations, and the study objectives follow directly.
“To meet the challenge of dopamine biodistribution and oxidation, a novel concept of continuous i.c.v. administration of an anaerobic dopamine formulation (A-dopamine) has been developed”
Randomization method is described (SAS-generated random numbers, concealed allocation). Blinding is partial: primary endpoint analysis blinded, but other outcomes open-label. Power analysis was initially for 20 patients but revised to 12 without a formal recalculation. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through per-protocol analysis excluding non-compliant weeks. Controls are inherent in the crossover design (oral treatment). Independent replication is not applicable for a single trial.
“Randomization sequence was created using a random number generated by the SAS 9.4 software in the Lille University Hospital biostatistics department.”
“The analysis of actimetry parameters, and in particular the primary endpoint, was blinded to patients and investigators.”
“The sample size was revised on 23 February 2023 following an amendment regarding the ability of the central pharmacy of Lille University Hospital to ensure the weekly production of A-dopamine under safe conditions for a maximum of 12 patients.”
“Randomization sequence was created using a random number generated by the SAS 9.4 software in the Lille University Hospital biostatistics department.”
“The analysis of actimetry parameters, and in particular the primary endpoint, was blinded to patients and investigators. Other parameters were analyzed openly for patients and investigators.”
“The sample size was revised on 23 February 2023 following an amendment regarding the ability of the central pharmacy of Lille University Hospital to ensure the weekly production of A-dopamine under safe conditions for a maximum of 12 patients.”
Sex is reported (9 male, 3 female). Age and health status are reported in baseline characteristics. Demographics include age, sex, and disease-related measures. Species/strain and housing conditions are not applicable for a human trial.
“The median age was 60.8 years (range: 53–69 years) and 9 patients were male (75.0%).”
“Since diagnosis, the median (range) duration of the disease, motor fluctuations and dyskinesia was 7.9 years (3.7–12.2 years), 4.3 years (1.2–8.3 years) and 2.4 years (0.2–5.3 years), respectively”
“The median age was 60.8 years (range: 53–69 years) and 9 patients were male (75.0%).”
The study was approved by a named ethics committee (French Ethics Committee of Amiens) with protocol numbers. Written informed consent was obtained from all participants. Compliance with ICH-GCP and Declaration of Helsinki is stated.
“The study was approved by the local independent ethics committee in 2020 (trial registration: protocol identifier: 2018_49; French Ethics Committee of Amiens: 2020-000155-12; French Drug Agency: MEDAECPP-2020-04-00002; ClinicalTrials.gov identifier: NCT04332276”
“All participants provided written informed consent before screening”
“The trial was conducted in accordance with the International Council for Harmonization Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki.”
“The study was approved by the local independent ethics committee in 2020 (trial registration: protocol identifier: 2018_49; French Ethics Committee of Amiens: 2020-000155-12; French Drug Agency: MEDAECPP-2020-04-00002; ClinicalTrials.gov identifier: NCT04332276”
“All participants provided written informed consent before screening, including knowledge of the plan to withhold dopaminergic medication unless necessary.”
“The trial was conducted in accordance with the International Council for Harmonization Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki.”
The investigational product (A-dopamine) is described with formulation details. The pump (Prometra II Flowonix) and catheter are named with manufacturers. Software used for randomization and analysis is identified. Antibodies, cell lines, and mycoplasma testing are not applicable.
“A-dopamine was formulated as a solution of dopamine hydrochloride (2, 10, 50 and 100 mg ml −1 ) dissolved in sodium chloride (0.9%) and sterile water for injection in a sterile anaerobic isolator”
“The catheter (Flowonix) implantation procedure through the right frontal horn into the third ventricle was performed by the neurosurgical team, with stereotactic placement of the catheter guided by Renishaw’s Neuro Mate robot.”
“All data were analyzed using the SAS software package, release 9.4 (SAS Institute), or using R software (R version 4.1.2).”
“The catheter (Flowonix) implantation procedure through the right frontal horn into the third ventricle was performed by the neurosurgical team, with stereotactic placement of the catheter guided by Renishaw’s Neuro Mate robot.”
“All data were analyzed using the SAS software package, release 9.4 (SAS Institute), or using R software (R version 4.1.2).”
The primary test (Wilcoxon signed-rank) is named. Effect sizes with CIs are reported for primary and secondary outcomes. However, many secondary outcomes report only effect sizes and CIs without p-values, which is acceptable per estimation approach, but some p-values are reported as thresholds (e.g., P = 0.027 is exact). Software is identified. Data presentation includes individual data in extended tables. Mathematical plausibility checks were not fully verifiable due to limited raw data.
“The primary outcome was compared between the two treatments using a paired Wilcoxon signed-rank test (performed on the intra-patient differences).”
“The A-dopamine effect size (standardized difference) was medium (Hedge’s g = −0.62 (95% confidence interval (CI): −1.43, −0.08)).”
“No statistical tests of comparisons were done for secondary and exploratory outcomes; only a descriptive analysis and an estimation of effect sizes are reported.”
“The primary outcome was compared between the two treatments using a paired Wilcoxon signed-rank test (performed on the intra-patient differences).”
The data availability statement says data will be available on reasonable request with a review committee, but lacks specific conditions and timeframe. No repository deposit or accession numbers are provided. Code availability is not mentioned.
“The data supporting the results will also be available on reasonable request from the corresponding author and C.M. (caroline.moreau@chu-lille.fr).”
“Statistical analyses were carried out independently by A. Duhamel and J.L. at the Lille University Hospital Biostatistics Department.”
“The data supporting the results will also be available on reasonable request from the corresponding author and C.M. (caroline.moreau@chu-lille.fr). Researchers should submit a request for access to pseudoanonymous patient-level clinical data, aggregated clinical data or anonymized clinical study documents.”
“Statistical analyses were carried out independently by A. Duhamel and J.L. at the Lille University Hospital Biostatistics Department.”
The trial is registered (NCT04332276). Methods are detailed. Limitations are discussed extensively. Conclusions are proportional. Funding and COI are disclosed. Reporting guideline (SPIRIT) is mentioned for the protocol.
“ClinicalTrials.gov registration: NCT04332276”
“However, this is a proof-of-concept study with several limitations that need to be discussed.”
“The study was funded by InBrain Pharma, France, a spin-off of the research academic team UMR-S 1172”
“ClinicalTrials.gov registration: NCT04332276”
“However, this is a proof-of-concept study with several limitations that need to be discussed. Firstly, the number of patients involved was limited.”
“The study was funded by InBrain Pharma, France, a spin-off of the research academic team UMR-S 1172 (University of Lille, INSERM, University Hospital of Lille), which delegated the promotion of the study to the University Hospital of Lille, France.”
Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 34 references by DOI: 34 verified.
Every extracted reference resolved against Crossref/OpenAlex with no retraction flags.
2 data/code links checked; 2 live.
- datahttps://clinicaltrials.gov/search?cond=NCT04332276LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT04332276LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
5 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 5 minor suggestions below.
5 copyedit issues flagged: mostly consistency, typo, clarity.
- MINORtypoAuthor affiliation 1“Univeristy of Lille”→ University of LilleTypographical error in affiliation.
- MINORconsistencyTable 4, LEDD reduction row“36 | 63 | 51 | 58 | 38 | 53 | 41 | 15 | 42 | 53 | 31 | 44 | 42 (15, 63)”→ Verify that the mean and median are correctly calculated from the individual values.The mean and median appear inconsistent with the listed values; check arithmetic.
- MINORconsistencyTable 2, LEDD reduction row“72.7 | 81.5 | 62.1 | 79.2 | 60.0 | 30.8 | 63.3 | 47.6 | 50.6 | 58.3 | 53.1 | 32.9 | 57.7 | 59.2 (30.8, 81.5)”→ Verify that the mean and median are correctly calculated from the individual values.The mean and median appear inconsistent with the listed values; check arithmetic.
- MINORconsistencyTable 4“LEDD reduction (%) | 36 | 63 | 51 | 58 | 38 | 53 | 41 | 15 | 42 | 53 | 31 | 44 | 42 (15, 63)”→ Check if the mean and median are correctly calculated; the mean of the listed values is 43.75, not 42.Potential arithmetic inconsistency in the mean LEDD reduction.
- MINORclarityMethods, Phase 2“Each sequence was composed of 2 periods of 4 weeks of treatment, and after 3 weeks of washout, patients crossed over to the other treatment.”→ Clarify whether the washout period is included in the 4-week treatment period or additional.Ambiguity in the crossover design description.
The published work is methodologically sound but has several reporting gaps that an informed reader should weigh: the sample size revision without recalculation, partial blinding, and vague data/code availability. These do not invalidate the findings but warrant caution and would benefit from a correction or clarification.
- 1.HIGHrigorAdd a formal sample size recalculation for the revised 12-patient target, including assumptions for effect size and power, in the Methods section.The sample size was revised without a formal recalculation, which is a major methodological gap that could affect the interpretation of the primary endpoint.
- 2.HIGHreportingClarify the blinding status for secondary outcomes and justify the open-label design for those measures in the Methods.The open-label design for secondary outcomes is a potential source of bias that should be explicitly acknowledged and justified.
- 3.HIGHstatisticsReport exact p-values for all secondary outcomes where hypothesis tests are performed, or explicitly state that only effect sizes are reported.Threshold-only p-values and missing p-values for secondary outcomes reduce transparency and hinder interpretation.
- 4.HIGHdata codeEnhance the data availability statement to include a specific access mechanism, conditions, and expected timeframe for data requests.The current 'on reasonable request' statement is vague and does not meet modern data-sharing expectations.
- 5.HIGHdata codeAdd a code availability statement, even if stating that no custom code was used, in the Code availability section.Lack of code sharing hinders reproducibility and is a common reviewer concern.
- 6.MEDIUMstatisticsInclude a statement on whether assumptions for the Wilcoxon test (e.g., symmetry of differences) were checked, in the Statistical analyses section.Verifying assumptions strengthens the statistical analysis and addresses a reviewer concern.
- 7.MEDIUMreportingConsider depositing de-identified individual patient data in a repository like Vivli or YODA to improve data accessibility.Repository deposit would significantly improve data availability and reproducibility.
- 8.MEDIUMreportingMention the reporting guideline used for the results (e.g., CONSORT) in the Methods or Reporting summary.Explicitly stating the reporting guideline improves transparency and completeness.
- 9.MEDIUMreportingProvide a CONSORT flow diagram in the main text to improve transparency of patient flow.A flow diagram clarifies patient disposition and is a standard requirement for clinical trials.
- 10.MEDIUMreportingInclude a statement on whether any patients were excluded from the safety analysis and why.Clarifying exclusions from safety analysis is important for completeness.
- 11.MEDIUMreportingSpecify the version of the Flowonix pump and catheter used, and any relevant lot numbers.Detailed device identification is important for reproducibility and safety assessment.
- 12.MEDIUMreportingAdd a note on the generalizability of the results given the small sample size and single-center design.Acknowledging limitations in generalizability is important for balanced interpretation.
- 13.MEDIUMcopyeditFix the typo 'Univeristy of Lille' to 'University of Lille' in the author affiliations.Correcting typos in affiliations is a basic copyedit requirement.
- 14.MEDIUMcopyeditVerify the arithmetic in Table 4 LEDD reduction row; the mean of the listed values appears to be 43.75, not 42.An internal inconsistency in reported summary statistics could undermine data credibility.
- 15.MEDIUMcopyeditVerify the arithmetic in Table 2 LEDD reduction row; the mean and median appear inconsistent with the listed values.Similar arithmetic inconsistency in another table suggests a potential data entry error.
- 16.LOWcopyeditClarify whether the washout period is included in the 4-week treatment period or additional in the Methods, Phase 2.Ambiguity in the crossover design description could confuse readers about the study timeline.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.